医学
结直肠癌
肿瘤科
内科学
全身疗法
疾病
生物标志物
癌症
佐剂
辅助治疗
局限性疾病
DPYD公司
心脏毒性
氟尿嘧啶
转移
总体生存率
临床实习
靶向治疗
作者
Al B. Benson,Alan Paul Venook,Mohamed Adam,Manju Ambelil,Alexander Bray,George J. Chang,Kristen Keon Ciombor,Stacey A. Cohen,Madison L. Conces,Dustin A. Deming,Vaia Florou,Ignacio Garrido‐Laguna,Jean L. Grem,Carla Harmath,Paul M. Haste,Joel Randolph Hecht,James Kevin Hicks,Sarah E. Hoffe,Steven R. Hunt,Hisham Hussan
标识
DOI:10.6004/jnccn.2026.0051
摘要
Colorectal cancer is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. Treatment of localized disease usually includes surgery, sometimes followed by adjuvant systemic therapy, while advanced or metastatic disease is often treated with multiple lines of systemic therapy, based on biomarker status. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Colon Cancer, including recommendations for pretreatment DPYD testing to decrease the risk of severe fluoropyrimidine toxicity; updates to adjuvant therapy of nonmetastatic colon cancer based on the results of recent clinical trials; and a reorganization of the systemic therapies for advanced or metastatic disease based on biomarker status, highlighting changes to the treatment recommendations for BRAF V600E mutation-positive disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI